Clinical Trials - Cancer Institute

The Scott & White Cancer Institute currently offers clinical trials for the following disease sites. Protocols are updated monthly to reflect currently open trials.

Cancer Prevention and Control Studies

• MDACC 2004-0024 - Chemotherapy and Mindfulness Relaxation: A Randomized Trial at M.D. Anderson Cancer Center and M.D. Anderson Community Clinical Oncology Program
• HLMCC 0501 - Stress Management Therapy for Patients Undergoing Chemotherapy for Cancer
• HLMCC 0502 - Thyroid Function and Breast Cancer. A Pilot Study to Estimate the Prevalence of Thyroid Dysfunction in women Diagnosed with Breast Cancer and the Magnitude of Change in Thyroid Function Post chemotherapy

Back to Top

Brain

There are no studies at this time.

Back to Top

Breast

Adjuvant Node Positive, Node Negative, Unknown

• NSABP B-43 - A Phase III Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiatin Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
• ECOG PACCT-1 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
• ECOG E5103 - A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer (NCI CIRB)

Metastatic

• 050319 - A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Tarvacin^TM ) in Patients with Refractory Advanced Solid Tumor Malignancies
• SWOG S0500 - A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at the First Follow-Up Assessment
• ECOG E1105 - A Randomized Phase III Double-Blind Placebo- Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over Expressing Metastatic Breast Cancer (NCI CIRB)
• 090009 - A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Capecitabine+Lapatinib in Patients With HER2-Positive Lically Advanced or Metastatic Breast Cancer Who Haave Received Prior Trastuzumab-Based Therapy

Other

• HLMCC 0502 - Thyroid Function and Breast Cancer. A Pilot Study to Estimate the Prevalence of Thyroid Dysfunction in Women Diagnosed with Breast Cancer and the Magnitude of Change in Thyroid Function Post chemotherapy
• MDACC 2004-0024 - Chemotherapy and Mindfulness Relaxation: A Randomized Trail at M.D. Anderson Cancer Center and M.D. Anderson Community Clinical Oncology Program

Back to Top

Gastrointestinal

Rectal

• NSABP R-04 - A Clinical Trial of Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in the Treatment of Patients with Operable Carcinoma of the Rectum

Colorectal

• 90250 - Double-blind Study, Comparing Efficacy of Aflibercerp vs. Placebo with MCRC treated with Irinotecan/5FU combination FOLFIRI after failure of oxaliplatin based regimen
• CTSU NCCTG N0147 - A Randomized Phase III Trial of Oxaliplatin Plus 5-FU/Leucovorin with or Without Cetuximab after Curative Resection for Patients with Stage III Colon Cancer

Metastatic

• MDACC 2008-0005 - Phase II, Randomized, Double Blind Compairson of CASAD vs Placebo for the Treatment and Prevention of Diarrhea in Patients with Metastatic Colorectal Cancer
• 81929 - Phase 2 Study to Compare Panitumumab in combination with mFOLFOX6 to Bevacizumab in combination with mFOLFOX6

Back to Top

Genitourinary

Prostate

• SWOG S0421 - A Phase III of Docetaxel And Atrasentan Versus Docetaxel And Placebo For Patients with Advanced Hormone Refractory Prostate Cancer

Renal

• ECOG E2805 - A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
• ECOG E4805 - A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVEOO5 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma

Bladder Cancer

• SWOG S0353 - Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG

Back to Top

Gynecologic

• 050319 - A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Tarvacin^TM) in Patients with Refractory Advanced Solid Tumor Malignancies
• GOG 136 - Acquisition of Human Gynecologic Specimens and Serum to be Used in Studying the Causes, Diagnosis, Prevention, and Treatment of Cancer

Back to Top

Head and Neck

There are no studies at this time

Back to Top

Leukemia/Lymphoma/Myeloma

Acute Myeloid Leukemia

• 22304 - Fusion Protein Therapy of Relapsed or Refractory and Elderly or Poor-Risk Acute Myeloid Leukemia (AML) with DT388IL3: A Phase I/II Clinical Trial

Leukemia

• ECOG E2903 - Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia

Myeloma

• ECOG E1A06 - An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) versus Melphalan, Prednisone and Lenalidomide (Revlimid) (MPR) in Newly Diagnosed Myeloma Patients Who Are Not Candidates for High Dose Therapy
  

Back to Top

Lung

• 050319 - A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Tarvacin^TM) in Patients with Refractory Advanced Solid Tumor Malignancies

Non-Small Cell

• ECOG E1505 - A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with completely Resected IB (>/= 4cm) - IIIA Non-Small Cell Lung Cancer
• 070969 - Phase 1/2 Study of Pemetrexed (Alimta®) plus Carboplatin, or Pemetrexed plus Cisplatin with Concurrent Radiation Therapy Followed by Every-21 Day Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B NSCLC
• GALGB 30607 - Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patient Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
• SWOG S0720 - Phase II ERCC 1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)
• 90040 ProActa - A Randomized Phase II, Multi-Center, Open Label Trial of PR104 and Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer

Small Cell Lung Cancer

• SWOG S0802 - A Randomized Phase II Trial of Weekly Topotecan With and Without AVE0005 in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer
  

Back to Top

Melanoma

Melanoma

• ECOG E1697 - Randomized Study of Four Weeks High Dose IFN-alpha 2b in Stage T3-T4 or N1 (microscopic) Melanoma
• SWOG S0826 - Phase II Trial of SCH 727965 in Patients with Stage IV Melanoma

Back to Top

Miscellaneous

Other

• HLMCC 0501 - Stress management therapy for patients undergoing chemotherapy

Solid Tumor

• 050319 - A Phase I Pharmacokinetics and Safety Study of Chimeric Anti-Phosphatidylserine Monoclonal Antiboey (Tarvacin) in Subjects with Advanced Solid Tumor Malignancies
• 060672 - An Open-Label, Multicenter Extension Study of Chimeric Ant-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients with Refractory Advanced Solid Tumor Malignancies (Must have completed 050319)

Clinical Trial Information:

For additional clinical trial information and screening for eligibility, please contact the Scott & White Center for Cancer Prevention and Care at 800-882-4366 or 254-724-1053.

Back to Top